Liver Disease

Liver diseases, often silent until advanced stages, present unique challenges for therapeutic intervention. At Muriphys, we specialize in preclinical models that shed light on the pathophysiology and treatment of rare and complex liver conditions. Our advanced drug delivery methods and comprehensive behavioral and metabolic assessments provide critical insights into diseases like Wilson’s disease, hemochromatosis, and familial hypercholesterolemia.

By partnering with Muriphys, you leverage cutting-edge technology and scientific expertise designed to accelerate the development of groundbreaking therapies for liver disorders.

Liver Diseases We Specialize In:

Wilson’s Disease
Wilson’s disease, characterized by copper accumulation in the liver and other organs, demands precision in both diagnosis and treatment. Muriphys offers preclinical models utilizing oral gavage, intravenous (IV), and intraperitoneal (IP) delivery to mimic real-world therapeutic approaches. Our metabolic chambers and imaging tools track disease progression, ensuring comprehensive evaluation of drug efficacy and copper chelation strategies. Read More.

Hemochromatosis
Excessive iron accumulation in hemochromatosis requires targeted therapeutic intervention. Muriphys employs intravenous, intraperitoneal, and oral drug delivery models to test iron chelation and organ protection strategies. With rotarod, open field, and treadmill assays, we evaluate systemic effects, while metabolic chambers monitor organ function and iron metabolism over time.

Familial Hypercholesterolemia
Familial hypercholesterolemia (FH) results in dangerously elevated cholesterol levels, increasing the risk of cardiovascular complications. Muriphys specializes in gene therapy models utilizing viral vectors, intravenous, subcutaneous (SC), and intraperitoneal (IP) delivery to target the liver’s genetic deficiencies. Our advanced imaging, rotarod, and metabolic chamber assessments track lipid profiles, cardiovascular markers, and overall metabolic health, ensuring a holistic approach to FH treatment development.

Why Muriphys for Liver Disease Research?

• Comprehensive Drug Delivery Platforms: From oral gavage to intravenous and intraperitoneal routes, our delivery systems reflect real-world therapeutic approaches, ensuring translatable preclinical results.
• Metabolic and Behavioral Analysis: Our metabolic chambers and behavioral tests provide in-depth assessments of systemic health, motor function, and metabolic performance, critical for evaluating liver disease progression and treatment outcomes.
• Advanced Imaging Capabilities: Cutting-edge imaging tools allow non-invasive monitoring of liver health, biodistribution and therapeutic response.
• Tailored Research Programs: Muriphys customizes every aspect of liver disease studies to reflect the specific pathophysiology and therapeutic targets, providing unparalleled insight into disease mechanisms and treatment efficacy.

Muriphys stands as a leader in liver disease research, offering the expertise and innovation necessary to unlock new therapeutic possibilities.

Transform liver disease research with Muriphys—where precision drives discovery and innovation leads to breakthroughs.